| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |